Company news

Neurogene Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial

March 3, 2024

Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer

January 15, 2024

Neurogene Announces Business Update and 2024 Outlook

January 4, 2024

Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split

December 13, 2023

Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

September 21, 2023

Neurogene and Neoleukin Announce Definitive Merger Agreement

July 17, 2023

Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition

March 7, 2023

Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting

December 11, 2022

Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update

November 13, 2022

Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting

November 2, 2022

Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate Update

August 8, 2022

Neoleukin Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference

August 2, 2022

Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022

July 26, 2022

Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA® (pembrolizumab)

May 15, 2022

Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update

May 8, 2022

Neoleukin Therapeutics to Present at Upcoming Investor Conferences

May 4, 2022

Neoleukin Therapeutics Announces Preclinical Data for NL-201 at American Association for Cancer Research (AACR) Annual Meeting

April 12, 2022

Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference

April 6, 2022

Neoleukin Therapeutics Announces Appointment of Donna Cochener as General Counsel

March 14, 2022

Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual Meeting

March 7, 2022

Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update

February 28, 2022

Neoleukin Therapeutics to Host 2021 Financial Results Conference Call and Webcast on March 1, 2022

February 21, 2022

Neoleukin Therapeutics to Present at Guggenheim Healthcare Talks 2022 Oncology Conference

February 2, 2022

Neoleukin Therapeutics Presenting at H.C. Wainwright BIOCONNECT Virtual Conference

January 9, 2022

Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with KEYTRUDA® (pembrolizumab)

January 9, 2022

Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021)

December 10, 2021

Neoleukin Therapeutics Presents NL-201 Preclinical Data at Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)

November 11, 2021

Neoleukin Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Update

November 3, 2021

Neoleukin Therapeutics Announces Multiple Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)

September 30, 2021

Neoleukin Therapeutics Announces Oral Presentation at IDWeek 2021 of Data Demonstrating that NL-CVX1, a Computationally Designed De Novo Protein, Can Block Infection by SARS-CoV-2 Viral Variants of Concern

September 28, 2021

Neoleukin Therapeutics Announces Appointment of Bill Arthur, Ph.D., as Vice President and Head of Research

September 8, 2021

Neoleukin Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

September 6, 2021

Neoleukin Therapeutics Announces Second Quarter 2021 Financial Results & Provides Corporate Update

August 4, 2021

Neoleukin Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference

August 3, 2021

Neoleukin Therapeutics to Participate in Jefferies Virtual Healthcare Conference

May 25, 2021

Neoleukin Therapeutics Announces First Quarter 2021 Financial Results and Corporate Update

May 11, 2021

Neoleukin Therapeutics Announces Initiation of Phase 1 NL-201 Trial

May 4, 2021

Neoleukin Therapeutics to Participate in BofA Securities 2021 Healthcare Conference

May 3, 2021

Neoleukin Therapeutics Announces Appointment of Priti Patel, M.D., M.S., as Chief Medical Officer

May 2, 2021

Neoleukin Therapeutics Announces Clearance to Proceed with NL-201 Phase 1 Clinical Trial in the United States

April 25, 2021

Neoleukin Therapeutics Announces Year End 2020 Financial Results

March 24, 2021

Neoleukin Therapeutics to Host 2020 Financial Results Conference Call and Webcast on March 25, 2021

March 17, 2021

Neoleukin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference

March 1, 2021

Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days

February 4, 2021

Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201

January 7, 2021

Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference

January 6, 2021

Neoleukin Therapeutics Announces Submission of Investigational New Drug Application for NL-201 De Novo Protein Immunotherapy Candidate for Cancer

December 9, 2020

Neoleukin Therapeutics Announces Participation in Piper Sandler 32nd Annual Virtual Healthcare Conference

November 22, 2020

Neoleukin Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

November 10, 2020

Neoleukin Therapeutics Presents Preclinical Combination Data for NL-201 at Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting (SITC 2020)

November 9, 2020

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 25 decks. Every deck is listed under its year.